Abuse Deterrence Advantage Egalet's Guardian Technology enables abuse-deterrent, extended-release formulations, aligning with opioid risk management trends. Their pipeline includes Egalet-002 for long-term opioid therapy. This creates business development opportunities with partners seeking to add or enhance abuse-deterrent properties in analgesics or other drug classes. Consider licensing or out-licensing deals.

Strategic Partnerships Historical collaborations with Septodont, Purdue Pharma, and Adare Pharmaceuticals indicate openness to alliances across dental, pediatric and geriatric formulations, and single-dose delivery. This suggests opportunities to re-engage these partners or identify new manufacturers seeking specialty formulation capabilities.

Contract Manufacturing As a small company with established products, Egalet could serve as a contract development and manufacturing partner for niche dosage forms, flavor masking, or Guardian-enabled formulations. Target mid-size to large pharma seeking specialized fill-finish capacity or co-development for pain therapies.

Regulatory Strategy Active engagement with regulatory authorities and experience with complex labeling points indicate capability to assist partners with regulatory strategy for abuse-deterrent products and analgesics. Potential services include regulatory consulting, pharmacovigilance, and market access planning.

Portfolio Diversification Guardian technology can be applied beyond opioids to other drug classes, offering opportunities to extend the pipeline through co-development and geographic expansion with the right partners. Explore non-opioid therapies or dental/medical device synergies and leverage agility to move deals forward.